MarketInOut Stock Screener Log In | Sign Up
 

MediciNova Inc

NASDAQ • Healthcare • Biotechnology • Quote as of 09/22/2026 11:49
MediciNova Inc stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization161.69 mln
Float47.81 mln
Earnings Date11/12/2026

Piotroski F-Score

4 / 9
Borderline

Beneish M-Score

1.33
Highly suspicious

1-Year Forecast

8.25
Transformational upside

Relative Strength

100 / 100
Top performer

Debt / Equity

0.00
Debt-free

Pre-Tax Margin

-1,168%
Severely loss-making

Business Description

MediciNova is a US-based pharmaceutical company focused on creating new oral treatments for serious illnesses that currently have few or no effective options. Its two lead drug candidates, ibudilast and tipelukast, are both in Phase 2 clinical trials targeting a range of conditions including multiple sclerosis, ALS, liver disease, and certain cancers. Founded in 2000 and based in La Jolla, California, the company continues to build its pipeline around small molecule compounds that can be taken by mouth.

Key Fundamentals

EPS-0.21
ROE-25.71
RPS0.02
ROIC-77.78
ROA-23.77
EBITDA, mln-11.83
EV / EBITDA-3.85
EV / EBIT-3.85
Revenue, mln0.92
EV / Revenue49.54

Quote Details

Last 3.08
Change -0.22 (-6.67%)
Open 3.16
Volume 2,092,466
Turnover 6,444,795
Average Volume 682,807

Financial Ratios

Pre-Tax Profit Margin-1,168
Leverage Ratio1.08
Current Ratio8.75
Price / Book1.90
Price / Tangible Book3.10
Debt / Equity0.00
Price / Sales75.79

Financial Strength

Altman Z-Score-2.09
Piotroski F-Score 4 / 9
Beneish M-Score1.33
1-Year Target Price8.25
Short Ratio9.92
Short % of Float0.77

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week 52.48% 99 / 100   
1 Month 122% 100 / 100   
2 Months 146% 99 / 100   
6 Months 112% 97 / 100   
1 Year 143% 97 / 100   



Disclaimer - Privacy Policy - Terms Of Service - Cookie Use Policy - FAQ - Contact Us